Cell Therapeutics [CTIC] 第3贴。..

白面包

sunny, 你不打算卖吗？

葉芬

10/2/2010

Cell Therapeutics, Inc. (CTIC) - Shares of Cell Therapeutics, Inc. were on fire Tuesday after the FDA will be rescheduling their advisory panel meeting. I will be avoiding the stock unless it breaks back above $1.24.

SUNNY仔

sunny, 你不打算卖吗？
白面包 发表于 9-2-2010 09:55 PM

    为什么要买咧....?我还想要再买来平衡..

bennywt

为什么要买咧....?我还想要再买来平衡..
SUNNY仔 发表于 11-2-2010 12:28 AM

老大，你有什么高见让你觉得他值得hold，而且坊间已经认定fda一定会reject 他的pix的要求。我其实也是想hold，可是想再观察一阵子。

葉芬

22/2/2010

Cell Therapeutics, Inc. (CTIC) - Shares of Cell Therapeutics, Inc. showed some strength Friday afternoon, breaking through the high of the day. The 10 day moving average is down to $0.75 which is a nice starting point for a recovery. I am watching $0.80, if Cell Therapeutics, Inc. breaks up through this level, I plan to buy.

葉芬

23/2/2010

Cell Therapeutics, Inc. (CTIC) - Shares of Cell Therapeutics, Inc. are now failing at the 10 day moving average. If Cell Therapeutics can break above the 10 day moving average and then close above $0.80, I will get back into the stock.

葉芬

24/2/2010

Cell Therapeutics, Inc. (CTIC) - Shares of Cell Therapeutics, Inc. continue to trade around $0.70. I will not buy Cell Therapeutics, Inc. unless it breaks above $0.80.

ken_teo85

0.69.... 慘咯......

kooilieng

好久没看CTIC了，刚刚开来看了一下，我的天啊！心脏都快掉出来了~~

拜天拜地，可千万不要BK才好啊！

SUNNY仔

好久没看CTIC了，刚刚开来看了一下，我的天啊！心脏都快掉出来了~~

拜天拜地，可千万不要BK才好啊！ ...
kooilieng 发表于 27-2-2010 02:35 PM

    哈哈..好久不见..别酱啦..我已习惯了..帐面亏损已二万马币了..

kooilieng

哈哈..好久不见..别酱啦..我已习惯了..帐面亏损已二万马币了..
SUNNY仔 发表于 2010-3-2 05:35 PM

我久久開來看一次，看到這樣的價錢，不下到才怪！
你有水，不怕不怕！
我好久沒有上msn了~~

pink0905

真的很怕bk。。。
ctic earning 在１５march。。
假如还是丢失很大我想还有的跌。。

韦一笑

是有点担心。。。因为没什么本可跌了。。ctic你要撑下去！！加油

pink0905

Cell Therapeutics Says FDA Set March 22 For ODAC Meeting To Review CTI's NDA For Pixantrone - Quick Facts



(RTTNews) - Cell Therapeutics, Inc. (CTIC) announced that the U.S. Food and Drug Administration's or FDA Oncologic Drugs Advisory Committee or ODAC will review CTI's New Drug Application or NDA for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma on March 22, 2010.

The company said that the meeting was to take place on February 10, 2010, but the FDA postponed the meeting because of severe weather conditions in the Washington, D.C. area. Following the vote at the rescheduled ODAC meeting, the FDA is expected to make a final decision on approval of CTI's NDA for pixantrone by April 23, 2010.

pink0905

Gynecologic Oncology Group (GOG) Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority


GOG-218 Bevacizumab Results Do Not Influence Importance of GOG-212


SEATTLE, March 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.  The Gynecologic Oncology Group (GOG) is one of the National Cancer Institute's (NCI) funded cooperative cancer research groups. The GOG is a multidisciplinary cooperative clinical trial research group focused on the study of gynecologic malignancies. The GOG is conducting phase III trials in ovarian cancer and other gynecologic cancers and has established standard treatments for these diseases in the U.S.

GOG leadership noted that, "GOG-218 and GOG-212 differ in the type of patients under study.  It is important to note that some of the patients who completed the initial 6 cycles of chemotherapy in GOG-218 had clinical evidence of persistent tumor and where randomized to either placebo (no treatment) or bevacizumab.  Thus a subset of GOG-218 patients received no therapy, despite the presence of persistent tumor.  This is not the typical setting of using maintenance or consolidation therapy and it is not the setting for patients enrolled in GOG-212.  In GOG-212, only patients who have achieved a complete clinical response are considered candidates for enrollment in the trial."

"Reliance upon the data from GOG-218 to establish the "standard of care" must take into consideration the actual treatment effect (i.e. duration of benefit), the cost of the treatment, and the associated toxicity...  [in GOG-212] the toxicity of the intervention may have less associated mortality and the incremental cost-effectiveness ratio may be more acceptable to patients and the health care economists. Thus the GOG has no intention to discontinue enrollment in GOG 212 as they feel that the study is addressing a different scientific question and the primary outcome study goal is survival, not progression free survival, an outcome of greater importance to both physicians and patients," the statement added.

The Data Monitoring Committee is scheduled to conduct an interim analysis of overall survival when 130 events are recorded among patients in the no maintenance treatment arm. The statistical analysis plan utilizes pre-specified boundaries for early stopping for success. Based on current enrollment and study duration, the interim analysis could be conducted as early as 2011. If successful, the Company could utilize those results to form the basis of its New Drug Application for OPAXIO.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of OPAXIO to prove safe and effective for the use as maintenance therapy in ovarian cancer as determined by the FDA, the risk that the GOG could decide to discontinue enrollment in the future, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

@.@MiKeY@.@

Speculation about the future of a few cancer drugs attracted a ton of interest in Seattle biotech this week.

The other local drama king that has a passionate following in the fast-money crowd—Seattle-based Cell Therapeutics—will indeed have its day in front of the FDA. Cell Therapeutics (NASDAQ: CTIC) had been planning to appear before an advisory panel on February 10 to argue for approval of its drug for non-Hodgkin’s lymphoma, but that day was snowed out in DC. The meeting has been rescheduled for March 22.

@.@MiKeY@.@

Pre-market last: 0.82 (+0.127)
Pre-market volume:85,305
Pre-market high:0.82
Pre-market low:0.732

07:29AM EST

v2_vehooi

你们敢博3月22日的court吗??

pink0905

回复 58# v2_vehooi


    已经在船上还给非常昂贵的船费。

乐静思

回复 59# pink0905

我也给了不少